To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.
Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.
China and Malaysia have agreed to build a high-level strategic China-Malaysia community with a shared future to accelerate their modernization efforts and jointly promote regional and global prosperity and stability.
GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.
Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that Health Canada has approved SPINEstat™, a first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), as a Class II medical device. By detecting auto-antibodies to the 14-3-3eta protein, SPINEstat™ provides an important new clinically validated and objective biomarker to aid in the early and accurate diagnosis of axSpA.
The number of foreigners coming to China has increased significantly in the first quarter of this year as a result of the continued improvement in the country's policies to facilitate cross-border travel, the National Immigration Administration said on Tuesday.
nSAGE, Caszyme, and Vilnius University have joined forces to form a consortium which will develop a new, advanced diagnostics solution. The UNCOVER project will develop a universal, CRISPR-based diagnostics platform for accurate and rapid detection of infectious diseases. This platform will be versatile, user-friendly, applicable to both human and animal health, and will be easily programable to address a wide range of pathogens and disease biomarkers.
Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
Chinese President Xi Jinping arrived in Hanoi on Monday to pay a state visit to Vietnam.
SCIEX, a global leader in life science analytical technologies, announces Chris Hagen as President, effective immediately. Hagen joins SCIEX from Beckman Coulter Diagnostics, a fellow Danaher operating company, where he most recently served as Senior Vice President and General Manager of Core Lab Specialty Solutions. As President of SCIEX, Hagen aims to motivate operational and commercial excellence while pushing the boundaries of innovation in analytical science.
President Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade probes led by the Commerce Department.
Dutch diagnostics firm Inbiome said Friday that it has received certification under the EU's In Vitro Diagnostic Regulation for a PCR-based test to aid the identification of more than 200 bacterial species from patient samples, with results within five hours.
Don’t miss important updates about the show and the in vitro diagnostic industry.
Sign-up for our newsletter today.
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.